Beam Therapeutics 3Q 2026: Revenue $307K, Net loss $134.4M, EPS $(1.28) — 10-Q Summary

What happened

Beam Therapeutics reported third-quarter 2026 revenue of $307K, down 96.8% from $9.7M a year earlier, and a net loss of $134.4M, or $1.28 per diluted share, widening from a $112.6M net loss, or $1.10 per diluted share.

Confirmed

Global impact / market context

Revenue nearly vanished while the net loss grew 19.4%, so the company is spending far more than it earns. That gap means future funding likely depends on borrowing, selling shares, or trial success, which can reduce each existing share's value.

Analyst inference

Beam is a loss-making gene-editing drug developer whose quarterly sales are tiny and erratic compared with research spending. Investors therefore judge it on clinical progress, such as the planned year-end 2026 license application for risto-cel, rather than on current profit.

Analyst inference

What to watch

1. Beam said a biologics license application for risto-cel may be filed by year-end 2026; that filing is a regulatory request to sell the treatment, and any delay would push revenue further out. Confirmed
2. Watch whether Beam discloses new financing plans, since a $134.4M quarterly loss means cash must be replenished; share sales would dilute owners, while borrowing adds interest costs. Proposed
3. Track enrollment in the BEAM-302 pivotal cohort and the 60 mg BEAM-301 cohort, plus BEAM-304 dosing expected in early 2027, because slow enrollment would delay any future product revenue. Analyst inference

Evidence

• Original source link unavailable